EGFR and lung carcinoma: The small molecule DNA-PK inhibitor, PI-103 or NU7441, combined with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Osimertinib, led to synergistic effects in TKI-resistant lung cancer cells.